Repligen (RGEN) opened 2026 with Q1 results that follow a year in which quarterly revenue ranged from about US$154.9 million to US$197.9 million and basic EPS moved between US$0.10 and US$0.27. Over that stretch, the company has seen revenue progress from US$154.9 million in Q3 2024 to US$197.9 million in Q4 2025, while basic EPS shifted from a loss of US$0.01 per share to a profit of US$0.24 per share, signaling a clear move back into positive territory. For investors, that pattern of growing sales alongside recovering EPS points to improving margins as a key theme behind the latest earnings release.

See our full analysis for Repligen.

With the numbers on the table, the next step is to see how this earnings profile lines up with the widely followed bull and bear narratives that have built up around Repligen over the past year.

Profitability Turns Around On A 12‑Month View

• On a trailing 12‑month basis, Repligen moved from a loss of US$25.5 million and basic EPS of US$0.46 in Q4 2024 to a profit of US$48.9 million and basic EPS of US$0.87 by Q4 2025, with trailing revenue over that span at US$738.3 million.
• What stands out for the bullish narrative is that this turnaround follows five years where earnings fell about 43.3% per year. Analysts are now expecting roughly 30.2% annual earnings growth and about 14.2% annual revenue growth, which creates a sharp contrast between the backward looking track record and the forward looking expectations.
  • Bulls point to the recent move into profitability and improving trailing EPS as evidence that higher margin products and operating leverage are starting to show up in the numbers.
  • At the same time, the earlier multi year earnings contraction keeps pressure on the bullish case to show that this is more than a short stretch of stronger quarters.

Bulls argue that this shift to positive earnings could be the start of a longer run, while others question how durable it is, so it can help to see how that bullish story is laid out in full before deciding where you stand on it. 🐂 Repligen Bull Case

Premium P/E Versus Peers At 144.9x

• Repligen currently trades on a trailing P/E of 144.9x against a peer average of 28.9x and a Global Life Sciences industry average of 36.5x, even though the stock price of US$125.61 is below both a DCF fair value of US$177.97 and an analyst price target of US$178.94.
• Skeptics highlight that paying a P/E multiple more than 4x the peer average leaves little room for disappointment, especially when five year earnings declined 43.3% per year. They therefore focus on whether expected growth and margins really justify such a premium.
  • The bearish narrative points to macro and customer concentration risks that could affect the forecast 30.2% annual earnings growth and 14.2% revenue growth and in turn challenge a valuation that already looks rich compared with the broader sector.
  • At the same time, trading below both the DCF fair value and the analyst target shows that even with a high trailing P/E, models and forecasts still sit above the current share price, which complicates a simple bearish view based only on multiples.

Bears often focus on the high P/E and prior earnings declines, so if you lean cautious it is worth seeing how that side of the argument is framed in more detail. 🐻 Repligen Bear Case

Revenue Base Near US$740m Supports Growth Debates

• Trailing 12‑month revenue has moved from US$633.5 million in Q3 2024 to US$738.3 million by Q4 2025, while quarterly revenue over 2025 ranged between US$169.2 million and US$197.9 million, giving a clearer sense of the scale that future growth forecasts build on.
• Analysts' consensus view leans on this roughly US$0.7b revenue base and improving profitability to support expectations of around 14.3% annual revenue growth and margins rising from 6.6% to 11.8% over the next few years, but the earlier period of weaker earnings and exposure to specific modalities means investors still have to judge how smooth that path is likely to be.
  • Consensus narrative points to expanding higher margin product lines and broader geographic reach as reasons the recent profitability could be sustained off this revenue base.
  • On the other hand, reliance on certain bioprocessing segments and funding sensitive biotech customers leaves room for actual growth to differ from those mid teens revenue assumptions.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Repligen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of optimism and caution in this earnings story, it helps to stress test the numbers yourself and see what stands out most. To see what the current optimism is based on, review the 4 key rewards.

Explore Alternatives

Repligen carries a trailing P/E of 144.9x after several years of earnings contraction, so a lot of optimism is already priced into the stock.

If that rich valuation makes you cautious, compare it with companies that combine quality fundamentals and more modest pricing by checking out the 51 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.